Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis
Year: 2026
Type: article
Abstract: Progression independent of relapses (PIRA) is a major therapeutic challenge in multiple sclerosis (MS). Nasal anti-CD3 treats animal models of progressive MS by inducing regulatory T cells (Tregs) that suppress CNS inflammation and lessen clinical disease.
Authors: Tanuja Chitnis, Tarun Singhal, Jonathan Zurawski, Taylor J. Saraceno, Niveditha Gopalakrishnan, Lauren Cain, Brenna LaBarre, Devin King, Regan W. Bergmark, Alice Z. Maxfield, Steven Cicero, Hong Pan, Shipra Dubey, Steven Vaquerano, Caleb Hansel, Brian C. Healy, Shrishti Saxena, Hrishikesh A. Lokhande, Moogeh Baharnoori, Evan Samuel Madill, Manali S. Sheth, Rachel Rodin, Jessica Ye, Nancy Clementi, William A. Clementi, Howard L. Weiner
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,450
OpenAlex ID: W7124424265